HIV infection and high density lipoprotein metabolism

Area of Science:

• Lipidology
• Virology
• Cardiovascular Medicine

Background:

• HIV infection and its treatments are linked to dyslipidemia and increased cardiovascular disease (CVD) risk.
• Understanding high-density lipoprotein (HDL) metabolism is crucial for managing CVD in HIV patients.

Purpose of the Study:

• To investigate HDL metabolism parameters in HIV-positive patients compared to HIV-negative controls.
• To assess the impact of HIV infection and antiretroviral therapy on lipid profiles and cholesterol transport.

Main Methods:

• Cross-sectional study comparing three groups: treatment-naïve HIV patients, HIV patients on protease inhibitors, and HIV-negative controls.
• Analysis of lipid parameters, including triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, apolipoproteins (apoB, apoA-I), lecithin cholesterol acyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and phospholipid transfer protein (PLTP).
• Assessment of plasma's ability to promote cholesterol efflux and correlation analysis with CD4+ cell counts.

Main Results:

• HIV-infected patients, irrespective of treatment, showed elevated triglycerides, apoB, LCAT mass/activity, and CETP compared to controls.
• All HIV-infected groups exhibited lower HDL cholesterol and prebeta(1)-HDL.
• ApoA-I levels and cholesterol efflux capacity were similar across groups, but PLTP was reduced in treated patients. A positive correlation was observed between apoA-I and CD4+ cell counts.

Conclusions:

• HIV infection significantly alters HDL metabolism, characterized by dyslipidemia and impaired reverse cholesterol transport.
• These metabolic changes may contribute to the increased cardiovascular risk observed in HIV-positive individuals.
• Antiretroviral therapy may further impact specific HDL-related proteins like PLTP.